Zhao Ruihua, Cao Xinguang, Jin Shuiling, Li Rui, Zhong Qian, Jiang Miao, Han Jinming, Guo Changqing, Zong Hong
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Digestive Disease, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Oncol. 2020 Aug 20;10:1392. doi: 10.3389/fonc.2020.01392. eCollection 2020.
The main reason for esophageal squamous cell carcinoma (ESCC) treatment failure is metastasis. Little is known about the mechanisms involved in the metastasis of ESCC, and there is a lack of effective therapeutic targets. In our previous study, we found that patients with high levels of BC200 tended to have poor prognoses. First, we applied qRT-PCR to detect the expression level of BC200 in normal esophageal squamous epithelial cells and ESCC cells with different degrees of differentiation ability. Then, we changed BC200 expression by transfecting constructed lentiviruses that included BC200 shRNA (LV-BC200-shRNA, KD), negative control (CON053, NC), or BC200 gene (LV-BC200, BC200) to create BC200-deficient cell models in KYSE410 and KYSE70 cells and BC200 overexpression cell models in EC9706 cells and verified the transfection effect by qRT-PCR. Then, we examined cell migration by wound healing assay, invasion by Transwell assay, and proliferation by MTT assay and examined the metastasis ability in a xenograft mouse model. Gene expression profiling was performed to screen a panel of mRNAs following inhibition of BC200 expression. We then used ingenuity pathway analysis (IPA) to analyze the functions of the changed molecules and their interactions. The results from the microarray were validated by qRT-PCR and Western blotting. In this study, we found that the expression of BC200 in poorly differentiated cell lines was significantly higher than that in well-differentiated cell lines. BC200 can significantly promote the migration and invasion but not the proliferation ability of ESCC cells and BC200 shRNA can significantly suppress tumor metastasis . Our genome-wide expression profile chip showed 406 differentially expressed genes, with 91 upregulated genes and 315 downregulated genes. The upstream regulator analysis showed that ATF4 was predicted to be strongly inhibited and 21 genes were consistently inhibited by this gene. Our qRT-PCR and Western blotting data also identified the reduced expression of ATF4 and some selected downstream genes, such as SNAIL2, GADD45A, and PSAT1, as a consequence of downregulating BC200 expression in ESCC. Our data showed that BC200 promoted the metastasis of ESCC cells and could regulate the expression of ATF4 and its downstream genes.
食管鳞状细胞癌(ESCC)治疗失败的主要原因是转移。目前对ESCC转移所涉及的机制了解甚少,并且缺乏有效的治疗靶点。在我们之前的研究中,我们发现BC200水平高的患者往往预后较差。首先,我们应用qRT-PCR检测BC200在正常食管鳞状上皮细胞以及具有不同分化能力的ESCC细胞中的表达水平。然后,我们通过转染构建的慢病毒来改变BC200的表达,这些慢病毒包括BC200 shRNA(LV-BC200-shRNA,KD)、阴性对照(CON053,NC)或BC200基因(LV-BC200,BC200),以在KYSE410和KYSE70细胞中创建BC200缺陷细胞模型,并在EC9706细胞中创建BC200过表达细胞模型,并用qRT-PCR验证转染效果。然后,我们通过伤口愈合试验检测细胞迁移,通过Transwell试验检测侵袭,通过MTT试验检测增殖,并在异种移植小鼠模型中检测转移能力。进行基因表达谱分析以筛选BC200表达受到抑制后的一组mRNA。然后,我们使用 Ingenuity 通路分析(IPA)来分析变化分子的功能及其相互作用。微阵列的结果通过qRT-PCR和蛋白质免疫印迹法进行验证。在本研究中,我们发现BC200在低分化细胞系中的表达明显高于高分化细胞系。BC200可显著促进ESCC细胞的迁移和侵袭,但不影响其增殖能力,并且BC200 shRNA可显著抑制肿瘤转移。我们的全基因组表达谱芯片显示有406个差异表达基因,其中91个上调基因和315个下调基因。上游调节因子分析表明,ATF4被预测受到强烈抑制,并且有21个基因受该基因持续抑制。我们的qRT-PCR和蛋白质免疫印迹数据还证实,由于ESCC中BC200表达下调,ATF4以及一些选定的下游基因(如SNAIL2、GADD45A和PSAT1)的表达降低。我们的数据表明,BC200促进ESCC细胞的转移,并可调节ATF4及其下游基因的表达。